We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Care4Today v2.0 Application for Improving Adherence to HIV Medications

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02001064
Recruitment Status : Completed
First Posted : December 4, 2013
Last Update Posted : November 3, 2014
Information provided by (Responsible Party):

November 27, 2013
December 4, 2013
November 3, 2014
October 2013
October 2014   (Final data collection date for primary outcome measure)
Adherence to Antiretroviral Medication [ Time Frame: Completion of 30-day intervention ]
Adherence will be measured using Medication Event Monitoring Systems (MEMS)
Same as current
Complete list of historical versions of study NCT02001064 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Care4Today v2.0 Application for Improving Adherence to HIV Medications
Pilot Study of Care4Today v.2.0 Application for Improving Adherence to HIV Medications

Although poor antiretroviral (ART) adherence in HIV does not mean a complete lack of therapeutic results, the benefit of ART increases as adherence improves. Consequences of suboptimal ART adherence are viral rebound, development of drug-resistant HIV strains, and more rapid progression to AIDS. Moreover, HIV-infected persons tend to have numerous co-occurring conditions and therefore take many medications making adherence to multiple drug regimens more difficult. A mobile application capable of improving medication adherence among HIV-infected persons would be highly useful.

The investigators propose an intervention study designed to address these potential mechanisms of nonadherence by utilizing the Care4Today v2.0 smartphone application (app). The current study is a small pilot Randomized Controlled Trial (RCT) comparing the smart phone application titled "Care4Today v2.0" versus standard of care to improve medication adherence to ART over a 4-week period with 60 HIV+ participants.

The pilot RCT consists of 60 HIV+ persons who are at risk for ART medication nonadherence. Using random assignment, 30 HIV+ participants will be assigned to medication adherence improvement via "Care4Today" app as compared to 30 HIV+ participants assigned standard of care.

The investigators will assess the effectiveness and acceptability of the app in improving objectively measured ART adherence (i.e., via medication event monitoring system caps) over a 4-week period via a pilot RCT with 30 HIV+ persons assigned to the Care4Today intervention and 30 HIV+ persons assigned to standard of care.

Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
  • HIV
  • AIDS
Behavioral: Application + Standard of care
Care4Today mobile application will send automated medication alert messages to HIV+ persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV+ persons who experience adherence difficulties over standard of care.
  • Experimental: Application + Standard of care
    Participants in the experimental application arm will use the Care4Today v2.0 mobile application for antiretroviral medication adherence support. Alert messages generated via the app will be targeted to the specific schedule and needs of the individual.
    Intervention: Behavioral: Application + Standard of care
  • No Intervention: Standard of care
    Participants will receive standard of care while on study.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
October 2014
October 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ability to provide informed consent
  • 18 years or older at the time of enrollment
  • HIV-infected
  • Taking at least one medication to treat HIV illness
  • Indication of medication nonadherence, or having a condition (e.g., active substance use, depression) that puts the individual at risk for medication non adherence
  • Willingness to use electronic monitoring caps to track ART medication
  • Willingness to respond to application alert messages

Exclusion Criteria:

  • Axis I psychiatric diagnosis of psychotic disorder or mood disorder with psychotic features
  • Presence of a neurological condition (beyond HIV infection) known to impact cognitive functioning (e.g., Huntington's Disease, Stroke)
  • Unwillingness or inability to use electronic medication monitoring technology
  • Unwillingness or inability to use daily alert messages
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
David J. Moore, Ph.D., University of California, San Diego
University of California, San Diego
Janssen Research & Development, LLC
Principal Investigator: David J. Moore, Ph.D. University of California, San Diego
University of California, San Diego
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP